Kolltan in-licenses cancer mAb from MedImmune
Executive Summary
Kolltan Pharmaceuticals Inc. (developing drugs that modulate receptor tyrosine kinase (RTK) function to treat cancer and other serious diseases) licensed rights to MedImmune LLC’s preclinical HER-3 (ErbB3) inhibitor. Kolltan plans to have the candidate in Phase I trials in early 2014.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice